-
Product Insights
Likelihood of Approval Analysis for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Overview How likely is it that the drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Familial hypercholesterolemia (FH)...
-
Product Insights
Likelihood of Approval Analysis for Mutational Disorders
Overview How likely is it that the drugs in Mutational Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mutational Disorders Overview Mutational disorders, alternatively termed genetic or genomic disorders, stem...
-
Product Insights
Likelihood of Approval Analysis for Neurofibromatoses
Overview How likely is it that the drugs in Neurofibromatoses will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Overview Neurofibromatosis (NF) is a term for a group of genetic disorders...
-
Product Insights
Likelihood of Approval Analysis for Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Overview How likely is it that the drugs in Neurofibromatoses Type I (Von Recklinghausen's Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Type I (Von Recklinghausen's Disease) Overview Neurofibromatosis...
-
Product Insights
Likelihood of Approval Analysis for Recessive X Chromosome Disorders
Overview How likely is it that the drugs in Recessive X Chromosome Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recessive X Chromosome Disorders Overview A recessive X chromosome disorder,...
-
Product Insights
Likelihood of Approval Analysis for X Chromosome Disorders
Overview How likely is it that the drugs in X Chromosome Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. X Chromosome Disorders Overview X chromosome disorders, also termed X-linked disorders,...
-
Product Insights
Likelihood of Approval Analysis for Myelofibrosis
Overview How likely is it that the drugs in Myelofibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Myelofibrosis Overview Myelofibrosis is a rare bone marrow disorder where abnormal cells cause...
-
Product Insights
Likelihood of Approval Analysis for Hemophilia A (Factor VIII Deficiency)
Overview How likely is it that the drugs in Hemophilia A (Factor VIII Deficiency) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hemophilia A (Factor VIII Deficiency) Overview Hemophilia A is...
-
Product Insights
Likelihood of Approval Analysis for Niemann-Pick Disease
Overview How likely is it that the drugs in Niemann-Pick Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niemann-Pick Disease Overview Acid sphingomyelinase deficiency (ASMD) is a rare genetic disorder...
-
Product Insights
Likelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...